This webinar will discuss a multigene approach to personalizing treatments for high blood pressure.
Although pharmacogenetic testing has become more widely adopted, providing patients with more genetically informed therapies, the vast majority of currently available clinical PGx testing focuses on genes involved in drug metabolism and transport. While these drug-metabolizing enzyme panels are important, there is evidence that in highly multifactorial diseases such as hypertension there are other genetic factors that strongly affect a patient’s response to therapies.
In this webinar, Dr. Ryan Sprissler of Geneticure will discuss a study examining these genetic determinants of hypertension therapy response that has shown that common and functional genetic variation plays a role in the variability of treatment effectiveness and may modulate the bell-curve response to many therapies.
Dr. Sprissler will share details on how these factors and subsequent trial data have led to the development of a multiplexed panel using a weighted algorithm to ultimately better predict individual therapy response.